The American Journal of Managed Care

SPIRIT-HF Shows No Significant Difference in HF Events With Spironolactone

SPIRIT-HF missed its primary composite endpoint at 2 years, with higher observed event rates on spironolactone versus placebo ...
Healio

Out of the loop: Augmenting diuresis with SGLT2 inhibitors in HF

SGLT2 inhibitors were first approved in 2013 for the treatment of type 2 diabetes. These agents act by blocking glucose and sodium reabsorption, thereby increasing glucose excretion. Glycosuria ...
Healio

Loop diuretic choice does not reduce all-cause death in HF: TRANSFORM-HF

Please provide your email address to receive an email when new articles are posted on . CHICAGO — A treatment strategy of torsemide vs. furosemide did not improve long-term clinical outcomes for ...
MedPage Today

Furosemide Holds Up to Newer, Stronger Loop Diuretic During HF Hospitalization

CHICAGO -- The choice between furosemide and torsemide didn't matter for longer-term clinical outcomes of hospitalized heart failure patients, according to the comparative effectiveness trial ...
Medscape

Should Torsemide Be the Loop Diuretic of Choice in Systolic Heart Failure?

In this comprehensive systematic review of randomized controlled trials, which included a total number of 471 patients, torsemide significantly reduced HF and CV-related hospital readmissions compared ...
Medscape

Clarity on Torsemide vs Furosemide in HF: TRANSFORM-HF Published

Survival and readmission risk were similar whether patients hospitalized with heart failure (HF) were discharged on furosemide or torsemide in a randomized trial entering the literature this week. The ...
The American Journal of Managed Care

New Research Calls for a Reconsideration of Loop Diuretic Use, Fluid Restriction in HF

Thirst outcomes were investigated among patients with stable heart failure (HF), due to the limited data available on this relationship and how it, along with fluid and sodium intake, influences ...